Eupraxia Pharmaceuticals, Inc. EPRX 深 滬
等待開盤 10-29 09:30:00 美东时间
7.38
+0.300
+4.24%
華盛通- 最 高7.42
- 今 開7.08
- 成交量 42.00万股
- 最 低 6.90
- 昨 收 7.08
- 總市值 4.88亿
- 52周最高 9.32
- 市盈率 靜 --
- 換手率 0.64%
- 52周最低 5.57
- 委 比 29.41%
- 總股本 6607.34万
- 歷史最高 9.32
- 量 比 0.99
- 振 幅 7.34%
- 歷史最低 2.20
- 每 手 1
- 風險率 0.87%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Eupraxia Pharmaceuticals to Participate at Upcoming Conferences and Host a Virtual Analyst Day
Eupraxia Pharmaceuticals Inc. announced that its management team will participate in several upcoming conferences and host a virtual Analyst Day. The events include the Craig Hallum Biotech Catalyst Virtual Conference on October 22, 2026, BIO-Europe in Cologne, Germany from November 9-11, 2026, the Stifel 2026 Healthcare Conference in New York from November 10-12, 2026, and the Jefferies Global Healthcare Conference in London from November 16-19,...
10-22 12:30
Eupraxia Pharmaceuticals to Present at Upcoming American College of Gastroenterology (ACG) and United European Gastroenterology (UEG) Medical Conferences
Eupraxia Pharmaceuticals Inc. announced that three abstracts related to its Phase 1b/2 RESOLVE trial of EP-104GI for treating eosinophilic esophagitis (EoE) have been accepted for presentation at the ACG 2026 Annual Scientific Meeting in Nashville and the UEG Week 2026 in Barcelona. The abstracts highlight improvements in dysphagia and histopathological features following single administration of EP-104GI. The RESOLVE trial evaluates the safety, ...
10-09 12:00
美股大行评级 | 潜在涨幅1654.39%！Ascendiant Capital上调NRX Pharmaceuticals(NRXP)目标价至50美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从49美元升至50美元；Ascendiant Capital：维持Atossa Therapeutics"买入"评级，目标价从24美元升至25美元
10-02 08:33
美股大行评级 | Meta获4家机构齐升目标价，最高看至995美元！麦当劳遭6家机构下调，最低看至260美元
今日重点评级关注：Canaccord Genuity：维持Aurora Innovation"买入"评级，目标价从15美元升至17美元；摩根大通：维持皇家加勒比邮轮"超配"评级，目标价从345美元升至394美元
09-25 15:55
Wedbush Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17
Wedbush analyst Martin Fan initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.
09-24 20:38
美股牛股 | Belite Bio飙升13.2%，获大行看高至303美元，潜在升幅约77%；存储、光通信板块逆势狂涨！Aehr Test Systems劲升13%，闪迪升近12%
Belite Bio飙升13.2%，获大行看高至303美元，潜在升幅约77%；存储、光通信板块逆势狂涨！Aehr Test Systems劲升13%，闪迪升近12%>>
09-05 06:25
Sirius XM, Dell, Ollie's Bargain Outlet And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mostly higher, with the Dow Jones index gaining around 250 points on Wednesday. Shares of Sirius XM Holdings Inc (NASDAQ:SIRI) rose sharply during Wednesday’s session after Deutsche Bank upgraded the stock from Hold to Buy and raised its price target from $31 to $45. Sirius XM share...
09-02 22:26
Eupraxia Pharmaceuticals Reports Symptom Response Data from its Ongoing Phase 1b/2a RESOLVE Trial, Including New Data on Odynophagia (Painful Swallowing) in Eosinophilic Esophagitis Patients
Eupraxia Pharmaceuticals Inc. announced positive results from the RESOLVE study, showing EP-104GI significantly reduces symptoms of odynophagia (pain swallowing) and dysphagia (difficulty swallowing) in EoE patients. Moderate to severe odynophagia dropped from 62% at baseline to 25% at 24-52 weeks, with no severe cases reported post-treatment. Similarly, moderate to severe dysphagia decreased from 77% to 25%. EP-104GI demonstrated good tolerabili...
08-13 12:00
Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline
Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 11.54 percent increase over losses of $(0.26) per share from the same period last year.
08-12 05:32
Eupraxia Pharmaceuticals Reports Second Quarter 2026 Financial Results
Eupraxia Pharmaceuticals Inc. announced its Q2 2026 financial results, reporting a net loss of $14.5 million, up from $8.7 million in Q2 2025, due to increased R&D and general expenses. The company highlighted positive data from its EP-104GI Phase 1b/2a trial in Eosinophilic Esophagitis (EoE), showing improvement in fibrosis and inflammation. Recent operational highlights include leadership appointments and the expansion of its EP-104GI target in...
08-11 21:21
